Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans

Elizabeth H. Sinz, Patrick M. Kochanek, Melvyn P. Heyes, Stephen R. Wisniewski, Michael J. Bell, Robert S B Clark, Steven T. DeKosky, Andrew R. Blight, Donald W. Marion

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

We tested the hypothesis that quinolinic acid, a tryptophan-derived N- methyl-D-aspartate agonist produced by macrophages and microglia, would be increased in CSF after severe traumatic brain injury (TBI) in humans, and that this increase would be associated with outcome. We also sought to determine whether therapeutic hypothermia reduced CSF quinolinic acid after injury. Samples of CSF (n = 230) were collected from ventricular catheters in 39 patients (16 to 73 years old) during the first week after TBI, (Glasgow Coma Scale [GCS] < 8). As part of an ongoing study, patients were randomized within 6 hours after injury to either hypothermia (32°C) or normothermia (37°C) treatments for 24 hours. Otherwise, patients received standard neurointensive care. Quinolinic acid was measured by mass spectrometry. Univariate and multivariate analyses were used to compare CSF quinolinic acid concentrations with age, gender, GCS, time after injury, mortality, and treatment (hypothermia versus normothermia). Quinolinic acid concentration in CSF increased maximally to 463 ± 128 nmol/L (mean ± SEM) at 72 to 83 hours after TBI. Normal values for quinolinic acid concentration in CSF are less than 50 nmol/L. Quinolinic acid concentration was increased 5-to 50-fold in many patients. There was a powerful association between time after TBI and increased quinolinic acid (P < 0.00001), and quinolinic acid was higher in patients who died than in survivors (P = 0.003). Age, gender, GCS, and treatment (32°C versus 37°C) did not correlate with CSF quinolinic acid. These data reveal a large increase in quinolinic acid concentration in CSF after TBI in humans and raise the possibility that this macrophage-derived excitotoxin may contribute to secondary damage.

Original languageEnglish (US)
Pages (from-to)610-615
Number of pages6
JournalJournal of Cerebral Blood Flow and Metabolism
Volume18
Issue number6
DOIs
StatePublished - Jan 1 1998

Fingerprint

Quinolinic Acid
Mortality
Glasgow Coma Scale
Hypothermia
Wounds and Injuries
Traumatic Brain Injury
Macrophages
Induced Hypothermia
Neurotoxins
Microglia
N-Methylaspartate
Tryptophan
Survivors
Mass Spectrometry
Reference Values
Therapeutics
Multivariate Analysis
Catheters

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Sinz, Elizabeth H. ; Kochanek, Patrick M. ; Heyes, Melvyn P. ; Wisniewski, Stephen R. ; Bell, Michael J. ; Clark, Robert S B ; DeKosky, Steven T. ; Blight, Andrew R. ; Marion, Donald W. / Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. In: Journal of Cerebral Blood Flow and Metabolism. 1998 ; Vol. 18, No. 6. pp. 610-615.
@article{a64a239773134c1ebeca8bb49d3db969,
title = "Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans",
abstract = "We tested the hypothesis that quinolinic acid, a tryptophan-derived N- methyl-D-aspartate agonist produced by macrophages and microglia, would be increased in CSF after severe traumatic brain injury (TBI) in humans, and that this increase would be associated with outcome. We also sought to determine whether therapeutic hypothermia reduced CSF quinolinic acid after injury. Samples of CSF (n = 230) were collected from ventricular catheters in 39 patients (16 to 73 years old) during the first week after TBI, (Glasgow Coma Scale [GCS] < 8). As part of an ongoing study, patients were randomized within 6 hours after injury to either hypothermia (32°C) or normothermia (37°C) treatments for 24 hours. Otherwise, patients received standard neurointensive care. Quinolinic acid was measured by mass spectrometry. Univariate and multivariate analyses were used to compare CSF quinolinic acid concentrations with age, gender, GCS, time after injury, mortality, and treatment (hypothermia versus normothermia). Quinolinic acid concentration in CSF increased maximally to 463 ± 128 nmol/L (mean ± SEM) at 72 to 83 hours after TBI. Normal values for quinolinic acid concentration in CSF are less than 50 nmol/L. Quinolinic acid concentration was increased 5-to 50-fold in many patients. There was a powerful association between time after TBI and increased quinolinic acid (P < 0.00001), and quinolinic acid was higher in patients who died than in survivors (P = 0.003). Age, gender, GCS, and treatment (32°C versus 37°C) did not correlate with CSF quinolinic acid. These data reveal a large increase in quinolinic acid concentration in CSF after TBI in humans and raise the possibility that this macrophage-derived excitotoxin may contribute to secondary damage.",
author = "Sinz, {Elizabeth H.} and Kochanek, {Patrick M.} and Heyes, {Melvyn P.} and Wisniewski, {Stephen R.} and Bell, {Michael J.} and Clark, {Robert S B} and DeKosky, {Steven T.} and Blight, {Andrew R.} and Marion, {Donald W.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1097/00004647-199806000-00002",
language = "English (US)",
volume = "18",
pages = "610--615",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "6",

}

Sinz, EH, Kochanek, PM, Heyes, MP, Wisniewski, SR, Bell, MJ, Clark, RSB, DeKosky, ST, Blight, AR & Marion, DW 1998, 'Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans', Journal of Cerebral Blood Flow and Metabolism, vol. 18, no. 6, pp. 610-615. https://doi.org/10.1097/00004647-199806000-00002

Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. / Sinz, Elizabeth H.; Kochanek, Patrick M.; Heyes, Melvyn P.; Wisniewski, Stephen R.; Bell, Michael J.; Clark, Robert S B; DeKosky, Steven T.; Blight, Andrew R.; Marion, Donald W.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 18, No. 6, 01.01.1998, p. 610-615.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans

AU - Sinz, Elizabeth H.

AU - Kochanek, Patrick M.

AU - Heyes, Melvyn P.

AU - Wisniewski, Stephen R.

AU - Bell, Michael J.

AU - Clark, Robert S B

AU - DeKosky, Steven T.

AU - Blight, Andrew R.

AU - Marion, Donald W.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - We tested the hypothesis that quinolinic acid, a tryptophan-derived N- methyl-D-aspartate agonist produced by macrophages and microglia, would be increased in CSF after severe traumatic brain injury (TBI) in humans, and that this increase would be associated with outcome. We also sought to determine whether therapeutic hypothermia reduced CSF quinolinic acid after injury. Samples of CSF (n = 230) were collected from ventricular catheters in 39 patients (16 to 73 years old) during the first week after TBI, (Glasgow Coma Scale [GCS] < 8). As part of an ongoing study, patients were randomized within 6 hours after injury to either hypothermia (32°C) or normothermia (37°C) treatments for 24 hours. Otherwise, patients received standard neurointensive care. Quinolinic acid was measured by mass spectrometry. Univariate and multivariate analyses were used to compare CSF quinolinic acid concentrations with age, gender, GCS, time after injury, mortality, and treatment (hypothermia versus normothermia). Quinolinic acid concentration in CSF increased maximally to 463 ± 128 nmol/L (mean ± SEM) at 72 to 83 hours after TBI. Normal values for quinolinic acid concentration in CSF are less than 50 nmol/L. Quinolinic acid concentration was increased 5-to 50-fold in many patients. There was a powerful association between time after TBI and increased quinolinic acid (P < 0.00001), and quinolinic acid was higher in patients who died than in survivors (P = 0.003). Age, gender, GCS, and treatment (32°C versus 37°C) did not correlate with CSF quinolinic acid. These data reveal a large increase in quinolinic acid concentration in CSF after TBI in humans and raise the possibility that this macrophage-derived excitotoxin may contribute to secondary damage.

AB - We tested the hypothesis that quinolinic acid, a tryptophan-derived N- methyl-D-aspartate agonist produced by macrophages and microglia, would be increased in CSF after severe traumatic brain injury (TBI) in humans, and that this increase would be associated with outcome. We also sought to determine whether therapeutic hypothermia reduced CSF quinolinic acid after injury. Samples of CSF (n = 230) were collected from ventricular catheters in 39 patients (16 to 73 years old) during the first week after TBI, (Glasgow Coma Scale [GCS] < 8). As part of an ongoing study, patients were randomized within 6 hours after injury to either hypothermia (32°C) or normothermia (37°C) treatments for 24 hours. Otherwise, patients received standard neurointensive care. Quinolinic acid was measured by mass spectrometry. Univariate and multivariate analyses were used to compare CSF quinolinic acid concentrations with age, gender, GCS, time after injury, mortality, and treatment (hypothermia versus normothermia). Quinolinic acid concentration in CSF increased maximally to 463 ± 128 nmol/L (mean ± SEM) at 72 to 83 hours after TBI. Normal values for quinolinic acid concentration in CSF are less than 50 nmol/L. Quinolinic acid concentration was increased 5-to 50-fold in many patients. There was a powerful association between time after TBI and increased quinolinic acid (P < 0.00001), and quinolinic acid was higher in patients who died than in survivors (P = 0.003). Age, gender, GCS, and treatment (32°C versus 37°C) did not correlate with CSF quinolinic acid. These data reveal a large increase in quinolinic acid concentration in CSF after TBI in humans and raise the possibility that this macrophage-derived excitotoxin may contribute to secondary damage.

UR - http://www.scopus.com/inward/record.url?scp=0031744449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031744449&partnerID=8YFLogxK

U2 - 10.1097/00004647-199806000-00002

DO - 10.1097/00004647-199806000-00002

M3 - Article

VL - 18

SP - 610

EP - 615

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 6

ER -